|
|
BC-3
|
|
|
Cornell Res. Fndn., Inc. |
|
Biosafety Level: |
2 [Cells contain Kaposi's sarcoma-associated herpesvirus genome ]
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
suspension |
|
|
Homo sapiens (human)
|
|
|
lymphoblast
|
|
|
Disease: lymphoma Cell Type: B lymphocyte; |
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
transfection host (Roche FuGENE® Transfection Reagents) |
|
|
CD30 +; CD38 +; CD45 +; CD 54 +; CD71 +; HLA-DR +; EMA + (epithelial membrane antigen); CD2 -; CD3 -; CD4 -; CD5 -, CD8 -; CD19 -; CD20 -; CD21 -; CD22 - |
|
|
Amelogenin: X CSF1PO: 11,12 D13S317: 11 D16S539: 12 D5S818: 11,12 D7S820: 10,12 THO1: 6,9 TPOX: 8,11 vWA: 14,18 |
|
|
85 years |
|
|
male |
|
|
Caucasian |
|
|
ATCC complete growth medium: RPMI 1640 medium, 80%; fetal bovine serum, 20%
|
|
|
Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 5 X 10 exp5 cells/ml and maintain between 5 X 10 exp5 and 2 X 10 exp6 cells/ml. |
|
|
Culture medium, 95%; DMSO, 5% |
|
|
23359: Arvanitakis L, et al. Establishment and characterization of a primary effusion (body cavity- based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 88: 2648-2654, 1996. PubMed: 8839859 39036: Cesarman E, et al. KSHV positive cell lines. US Patent 5,908,773 dated Jun 1 1999 |